Explore treatment pathways from early-stage differentiated thyroid cancer to advanced medullary and anaplastic forms.
Free to use — Live data from ClinicalTrials.gov — Updated hourly
Answer a few questions about your condition and we'll match you to the most relevant clinical trials.
See where clinical trials fit into your treatment journey
Papillary or follicular thyroid cancer — often curable with surgery
Standard: Surgery (thyroidectomy) ± radioactive iodine ablation, TSH suppression
Cancer no longer responds to radioactive iodine treatment
Standard: Lenvatinib or Sorafenib (tyrosine kinase inhibitors)
Rare type arising from C-cells, often hereditary (MEN2)
Standard: Vandetanib or Cabozantinib for advanced disease
Rare, aggressive form requiring rapid treatment
Standard: Combination chemo-radiotherapy, immunotherapy trials emerging
Found in ~45% of papillary thyroid cancers. Predicts response to BRAF-targeted therapies and informs radioactive iodine sensitivity.
Present in nearly all medullary thyroid cancers. RET inhibitors (Selpercatinib, Pralsetinib) target this mutation specifically.
Found in ~5% of thyroid cancers. NTRK inhibitor trials (Larotrectinib, Entrectinib) are available for fusion-positive tumours.
Common in follicular thyroid cancer. May indicate progression risk and influence treatment choices.
Loading trials from ClinicalTrials.gov...
Yes. Several trials target BRAF mutations, RET fusions, and NTRK fusions in thyroid cancer. Newer trials also explore immunotherapy combinations, particularly for iodine-refractory and anaplastic thyroid cancer.
When thyroid cancer no longer responds to radioactive iodine treatment (RAI-refractory), targeted therapies like Lenvatinib or Sorafenib become the standard option. Clinical trials offer access to newer TKIs and immunotherapy approaches.
Yes. Medullary thyroid cancer (MTC) has specific trials for RET inhibitors like Selpercatinib and Pralsetinib. There are also trials exploring combination approaches for progressive or advanced MTC.
Use our search above to find trials that match your condition and location. Review the eligibility criteria carefully.
Talk to your GP or specialist about any trials you are interested in. They can help determine if a trial is appropriate for you.
Reach out to the trial team directly using the contact information on the ClinicalTrials.gov listing. They will guide you through screening.
If you meet the criteria and decide to participate, you will go through informed consent and begin the trial process.